Navigation Links
Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
Date:8/22/2007

ore concentrated dose and expect data from this trial in 2008."

About Catheter Occlusion

Delivery of chemotherapy, nutritional support, antibiotics and blood products, as well as the frequent withdrawal of blood samples for laboratory testing, are often facilitated via central venous catheters. Approximately five million catheters are placed in patients in the United States each year, with as many as 25 percent becoming occluded. When a catheter becomes occluded, the goal is to restore flow in a prompt and cost-effective manner with minimal risk to the patient. As these catheters are primarily inserted in patients receiving life-saving medications such as chemotherapy, it is critical to restore flow through the catheter as soon as possible. In the case of thrombotic occlusions, treatment with thrombolytic drugs represents a less-invasive and more cost-effective alternative to replacement.

About Alfimeprase

Alfimeprase is a recombinant direct acting fibrinolytic (rDAF) that has the potential to rapidly dissolve blood clots through a unique mechanism of action -- it directly degrades fibrin, a protein that provides the scaffolding for blood clots. In addition, alfimeprase's thrombolytic activity appears to be localized to the site of delivery because it is rapidly inactivated by alpha-2 macroglobulin, a naturally occurring protein in the blood, as it moves away from the site of delivery and into the general blood circulation.

In addition to catheter occlusion, alfimeprase is also being evaluated as a potential treatment for acute ischemic stroke and is in preclinical studies for acute peripheral arterial occlusion.

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic-related disor
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
3. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
4. Nuvelo Announces Publication of NU206 Study Results in Gastroenterology
5. Nuvelo Announces Presentation on NU206 at 2007 American Association for Cancer Research Annual Meeting
6. Nuvelo Announces Presentation on rNAPc2 at American College of Cardiology 56th Annual Scientific Session
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... -- This report analyzes the worldwide markets for Foot Care ... Medication. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2013 ... these markets. Market data and analytics are derived from primary ...
(Date:9/16/2014)... , Sept. 16, 2014 Research and Markets ... Vaccines Market 2014-2018" report to their offering. ... immunity of animals. Animal vaccines are generally prepared from weakened ... in their healthy state. Some of the animal vaccines are ... as protein subunits or toxic components. These ...
(Date:9/16/2014)... Sept. 16, 2014 Adaptive Biotechnologies, a clinical ... to profile the adaptive immune system, is pleased to ... Chief Commercial Officer (CCO). The addition of Brain to ... hires from leading global healthcare companies, including Dean ... Counsel) from Genomic Health and Sean Nolan ...
Breaking Medicine Technology:Global Foot Care Products Industry 2Global Foot Care Products Industry 3Global Foot Care Products Industry 4Global Foot Care Products Industry 5Global Foot Care Products Industry 6Global Foot Care Products Industry 7Global Foot Care Products Industry 8Global Foot Care Products Industry 9Global Foot Care Products Industry 10Global Foot Care Products Industry 11Global Foot Care Products Industry 12Global Foot Care Products Industry 13Global Foot Care Products Industry 14Global Foot Care Products Industry 15Global Foot Care Products Industry 16Global Foot Care Products Industry 17Global Foot Care Products Industry 18Global Foot Care Products Industry 19Global Foot Care Products Industry 20Global Foot Care Products Industry 21Global Foot Care Products Industry 22Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 2Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 3Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3
... N.J., May 24, 2012 Watson Pharmaceuticals, Inc. ... its subsidiary, Watson Laboratories, Inc., filed an Abbreviated ... and Drug Administration (FDA) seeking approval to market ... is a generic version of Auxilium Pharmaceuticals, Inc.,s ...
... ANTONIO, May 24, 2012 /PRNewswire-iReach/ -- An ... Life Science Venture Forum in Houston, Texas named TransCU ... of ten Most Promising Life Science Technologies .  ... and innovations to hundreds of early-stage investors, venture capitalists, ...
Cached Medicine Technology:Watson Confirms Testim® Patent Challenge 2Watson Confirms Testim® Patent Challenge 3New Chronic Wound Therapy Awarded at Texas' Largest Life Science Event 2
(Date:9/16/2014)... LINCOLN, R.I. (PRWEB) September 16, 2014 ... from Sunday, Sept. 14, through Saturday, Sept. 20, ... make sure children are safe and secure while in ... from the National Traffic Highway Safety Administration (NHTSA), ... did not read the instruction manual when installing child ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Regulatory ... available regulatory information, has become a crucial skill ... device and biotechnology sectors. Regulatory Intelligence 101 ... Society (RAPS) serves as an essential guide ... Regulatory Intelligence 101 examines available regulatory intelligence tools, ...
(Date:9/16/2014)... (HealthDay News) -- Illegal drug use among teens in the ... federal report. Encouragingly, the new study also found ... products among young people between the ages of 12 and ... survey of 70,000 people aged 12 and older across the ... or abuse problems among this age group also dropped from ...
(Date:9/16/2014)... San Francisco, September 15, 2014Patients with inoperable, early-stage ... (SBRT) have a five-year survival rate of 40 ... American Society for Radiation Oncology,s (ASTRO,s) 56th Annual ... considering that historically conventional RT resulted in poor ... This study is an update of RTOG 0236, ...
(Date:9/16/2014)... of researchers at Boston University and Stanford University School ... the motion patterns of bacteria in real time and ... a bacterial colony. , The researchers chemically attached colonies ... a microscopic beam anchored at one end, similar ... to that of the bacteria. As the cantilever itself ...
Breaking Medicine News(10 mins):Health News:Amica Offers Tips During Child Passenger Safety Week 2Health News:RAPS Publishes Regulatory Intelligence 101 Book 2Health News:Fewer U.S. Teens Using Illegal Drugs and Alcohol, Report Finds 2Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 2Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 3Health News:And so they beat on, flagella against the cantilever 2
... kinesin CENP-E (GSK923295A) demonstrates a novel mechanism of inhibiting ... panel of human tumor cell lines in vitro: Abstract ... designed to inhibit a single protein that functions only ... range of cancer cell lines, say researchers from GlaxoSmithKline. ...
... Pharmaceuticals, a New,Jersey-based developer, manufacturer and distributor ... API and finished,dosages development and manufacturing company ... to develop, manufacture, market and distribute,several products ... product pipeline,will include at least ten ophthalmic ...
... Members of Congress Call Today for a "Medicare-Operated" ... adults and persons,with disabilities should have the option ... program to eliminate the consumer,exploitation that plagues the ... insurance companies, concludes Consumers Union and the Medicare,Rights ...
... Standards Panel (HITSP) has identified a set of,standards ... medical,information secure in an electronic environment. The standards ... only be used by authorized,personnel for official purposes., ... and privacy architecture is,the latest in a series ...
... medical care, researchers suggest , , TUESDAY, Oct. 23 (HealthDay News) ... remained constant since 2000, with some one-third of all Americans ... , But less than 25 percent of those at high ... sex or are intravenous drug users -- have been tested ...
... Affordable Treatments for the World,s ... episode of the Charlie Rose Science Series will ... -- ranging from the AIDS crisis to malaria, ... neglected diseases. A group of experts ...
Cached Medicine News:Health News:Experimental cancer pharmaceuticals under trial 2Health News:Amneal Pharmaceuticals & Indoco Remedies Finalize Long Term Joint Venture Agreement to Develop and Market Generic Ophthalmic Pharmaceuticals 2Health News:Amneal Pharmaceuticals & Indoco Remedies Finalize Long Term Joint Venture Agreement to Develop and Market Generic Ophthalmic Pharmaceuticals 3Health News:Report: Medicare-Administered Drug Benefit Would be More Affordable, Comprehensive, Stable than Current Private Insurance-Run Drug Benefit 2Health News:Report: Medicare-Administered Drug Benefit Would be More Affordable, Comprehensive, Stable than Current Private Insurance-Run Drug Benefit 3Health News:HITSP Defines Overarching Set of Healthcare Security and Privacy Standards 2Health News:Many at Risk for HIV Not Being Tested 2Health News:Many at Risk for HIV Not Being Tested 3Health News:Charlie Rose Science Series Episode #10 - GLOBAL HEALTH October 29, 2007 2
... KIMBERLY-CLARK CLOtest Rapid Urease Test is ... Standard among urease tests because of its ... by Barry Marshall, MD. who, along with ... discover the correlation between H. pylori and ...
... Rapid Test Strip and Device are rapid ... antibodies to Helicobacter pylori (H. pylori) in ... in the diagnosis of H. pylori infection ... older. They are intended for health professionals ...
... pylori WB test is a ... detection of lgG antibodies specific ... whole blood. This test kit ... in the diagnosis of H.pylori ...
... based on a lateral flow chromatography ... the qualitative detection of Helicobacter pylori ... Platinum HpSA, a microtiter assay from ... accepted as an accurate tool for ...
Medicine Products: